Unique ID issued by UMIN | UMIN000026912 |
---|---|
Receipt number | R000030869 |
Scientific Title | The observational study on efficacy of oral anticoagulants for cognitive dysfunctions of the patients after cerebral infarction in super-aged society |
Date of disclosure of the study information | 2017/07/01 |
Last modified on | 2017/04/09 00:17:37 |
The observational study on efficacy of oral anticoagulants for cognitive dysfunctions of the patients after cerebral infarction in super-aged society
The study on NOAC for prevention of dementia after stroke
The observational study on efficacy of oral anticoagulants for cognitive dysfunctions of the patients after cerebral infarction in super-aged society
The study on NOAC for prevention of dementia after stroke
Japan |
non-valvular atrial fibrillation (NVAF)
Neurology |
Others
NO
to investigate the efficacy of NOAC (non-vitamin K antagonist oral anticoagulant) for reduction of a risk at cognitive dysfunction after cerebral infarction of the patients with NVAF.
Safety
Confirmatory
Others
Not applicable
the change of MMSE (mini-mental state examination) score between baseline and after 2 years of the registration
1) occurrences of death from any cause, dementia, stroke, and cardiovascular events
2) the change of CDR score
3) the change of MoCA score
4) occurrences of hemorrhagic events
5) occurrences of ischemic events
Observational
50 | years-old | <= |
100 | years-old | > |
Male and Female
1) non-valvular atrial fibrillation
2) the use of oral anticoagulants (warfarin and NOACs)
3) CDR 0-0.5 and MMSE 24-30
4) informed consent is obtained
5) the age over 49 and under 100 year-old
6) the patients after cerebral infarction (over 6 months after the onset)
1) valvular atrial fibrillation
2) CDR>0.5 or MMSE<24
3) the patients after cerebral infarction (under 6 months after the onset)
4) Parkinson disease, Huntington disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, epilepsy, subdural hematoma, encephalitis/meningitis, multiple sclerosis, or cognitive decline by head trauma
5) depression, schizophrenia, alcoholism, drug dependence, or other critical disease
6) deficiency of vitamin B1, B12, or folic acid, syphilis, or hypothyroidism
7) difficult to perform the neuropsychological examination
8) other inappropriate state assessed by the researchers
160
1st name | |
Middle name | |
Last name | Koji Abe |
Okayama University Hospital
Department of Neurology
2-5-1, Shikata-cho, Kita-ku, Okayama, Japan
086-235-7365
yumikonakano@okayama-u.ac.jp
1st name | |
Middle name | |
Last name | Yumiko Nakano |
Okayama University Hospital
Department of Neurology
2-5-1, Shikata-cho, Kita-ku, Okayama, Japan
086-235-7365
yumikonakano@okayama-u.ac.jp
Okayama University Hospital, Department of Neurology
Japan Society for the Promotion of Science
Japanese Governmental office
Japan
NO
岡山大学病院(岡山県)
2017 | Year | 07 | Month | 01 | Day |
Unpublished
Preinitiation
2017 | Year | 04 | Month | 08 | Day |
2017 | Year | 08 | Month | 01 | Day |
2021 | Year | 03 | Month | 31 | Day |
We will include the patients with non-valvular atrial fibrillation (NVAF) who are over 49 and under 100 year-old after 6 months of cerebral infarction and use the oral anticoagulants. We will compare the MMSE after 2 years of registration to baseline, and validate the reduction for a risk at cognitive dysfunction in these patients.
2017 | Year | 04 | Month | 09 | Day |
2017 | Year | 04 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030869